Myriad Genetics was handed a win a few weeks ago when a federal appeals court ruled in the company's favor and upheld its BRCA gene patents. However, the court also struck down Myriad's methods patents. So now, both sides — Myriad and the plaintiffs represented by the ACLU — are asking the court to review its decision, though for different reasons, says Genomics Law Report's John Conley.